NextSource Biotechnology: FDA Approves NextSource's Brain Tumor Treatment
NewsNextSource Biotechnology gains FDA approval for new 5 mg strength of Gleostine® (lomustine), an anti-cancer chemotherapy agent.Contributed Author: Business WireTopics: Regulatory
Read full article »
NextSource Biotechnology manufactures and consolidates pharmaceutical products to reduce drug shortage and maintains a consistent supply of medicines.
Read more